About marker therapeutics - MRKR
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.
MRKR At a Glance
Marker Therapeutics, Inc.
2450 Holcombe Boulevard
Houston, Texas 77021
| Phone | 1-713-400-6400 | Revenue | 6.59M | |
| Industry | Biotechnology | Net Income | -10,731,315.00 | |
| Sector | Health Technology | 2024 Sales Growth | 99.058% | |
| Fiscal Year-end | 12 / 2025 | Employees | 5 | |
| View SEC Filings |
MRKR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 4.237 |
| Price to Book Ratio | 1.793 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.786 |
| Enterprise Value to Sales | 1.325 |
| Total Debt to Enterprise Value | N/A |
MRKR Efficiency
| Revenue/Employee | 1,318,216.00 |
| Income Per Employee | -2,146,263.00 |
| Receivables Turnover | 2.809 |
| Total Asset Turnover | 0.337 |
MRKR Liquidity
| Current Ratio | 6.357 |
| Quick Ratio | 6.357 |
| Cash Ratio | 5.54 |
MRKR Profitability
| Gross Margin | N/A |
| Operating Margin | -168.688 |
| Pretax Margin | -162.058 |
| Net Margin | -162.816 |
| Return on Assets | -54.821 |
| Return on Equity | -65.814 |
| Return on Total Capital | -57.825 |
| Return on Invested Capital | -65.814 |
MRKR Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |